Performance of the CMS Cathode Strip Chambers with Cosmic Rays

The Cathode Strip Chambers (CSCs) constitute the primary muon tracking device in the CMS endcaps. Their performance has been evaluated using data taken during a cosmic ray run in fall 2008. Measured noise levels are low, with the number of noisy channels well below 1%. Coordinate resolution was measured for all types of chambers, and fall in the range 47 microns to 243 microns. The efficiencies for local charged track triggers, for hit and for segments reconstruction were measured, and are above 99%. The timing resolution per layer is approximately 5 ns

Performance and Operation of the CMS Electromagnetic Calorimeter

The operation and general performance of the CMS electromagnetic calorimeter using cosmic-ray muons are described. These muons were recorded after the closure of the CMS detector in late 2008. The calorimeter is made of lead tungstate crystals and the overall status of the 75848 channels corresponding to the barrel and endcap detectors is reported. The stability of crucial operational parameters, such as high voltage, temperature and electronic noise, is summarised and the performance of the light monitoring system is presented

How does study quality affect the results of a diagnostic meta-analysis?

Background: The use of systematic literature review to inform evidence based practice in diagnostics is rapidly expanding. Although the primary diagnostic literature is extensive, studies are often of low methodological quality or poorly reported. There has been no rigorously evaluated, evidence based tool to assess the methodological quality of diagnostic studies. The primary objective of this study was to determine the extent to which variations in the quality of primary studies impact the results of a diagnostic meta-analysis and whether this differs with diagnostic test type. A secondary objective was to contribute to the evaluation of QUADAS, an evidence-based tool for the assessment of quality in diagnostic accuracy studies. Methods: This study was conducted as part of large systematic review of tests used in the diagnosis and further investigation of urinary tract infection (UTI) in children. All studies included in this review were assessed using QUADAS, an evidence-based tool for the assessment of quality in systematic reviews of diagnostic accuracy studies. The impact of individual components of QUADAS on a summary measure of diagnostic accuracy was investigated using regression analysis. The review divided the diagnosis and further investigation of UTI into the following three clinical stages: diagnosis of UTI, localisation of infection, and further investigation of the UTI. Each stage used different types of diagnostic test, which were considered to involve different quality concerns. Results: Many of the studies included in our review were poorly reported. The proportion of QUADAS items fulfilled was similar for studies in different sections of the review. However, as might be expected, the individual items fulfilled differed between the three clinical stages. Regression analysis found that different items showed a strong association with test performance for the different tests evaluated. These differences were observed both within and between the three clinical stages assessed by the review. The results of regression analyses were also affected by whether or not a weighting (by sample size) was applied. Our analysis was severely limited by the completeness of reporting and the differences between the index tests evaluated and the reference standards used to confirm diagnoses in the primary studies. Few tests were evaluated by sufficient studies to allow meaningful use of meta-analytic pooling and investigation of heterogeneity. This meant that further analysis to investigate heterogeneity could only be undertaken using a subset of studies, and that the findings are open to various interpretations. Conclusion: Further work is needed to investigate the influence of methodological quality on the results of diagnostic meta-analyses. Large data sets of well-reported primary studies are needed to address this question. Without significant improvements in the completeness of reporting of primary studies, progress in this area will be limited

Lesiones neoplásicas sincrónicas en cáncer colorrectal. Experiencia en el Hospital Clínico Regional de Valdivia

Se comunica nuestra experiencia en lesiones neoplásicas sincrónicas en cáncer colorrectal de pacientes tratados en el Servicio de Cirugía Adulto del Hospital Clínico Regional de Valdivia. Se revisó retrospectivamente los antecedentes de los pacientes operados por cáncer colorrectal entre Enero de 1990 hasta Junio de 1999. En ese período se encontraron 153 pacientes operados por cáncer colorrectal, de los cuales 18 (11.8%) presentaban lesiones neoplásicas sincrónicas. Nueve (5.9%) de ellos fueron adenocarcinomas. La media de la edad de la serie fue de 58.5 años. Existió predominio de hombres sobre las mujeres (11:7). La colonoscopia larga se usó en 8 pacientes y en 5 de ellos se planificó la cirugía de acuerdo a los hallazgos de este procedimiento, debiéndose ampliar la resección colónica programada inicialmente. Todas las lesiones primarias fueron estadificadas como avanzadas. Se encontraron pólipos en 8 casos, 5 de los cuales fueron múltiples, en su mayoría adenomas. El seguimiento de los enfermos fluctuó entre 2 y 86 meses. Al cierre de la revisión se encuentran 8 pacientes en control, 5 fallecidos y 5 perdidos de control. En nuestra pequeña serie observamos un mayor número de cánceres sincrónicos con relación a lo publicado por otros autores nacionales. La edad de presentación es aparentemente menor que el cáncer colorrectal en general y existiría un predominio del sexo masculino. Nuestro estudio sugiere que todo paciente con cáncer colorrectal debería estudiarse con colonoscopia larga, idealmente realizada en el período preoperatorio

Anthropozoonotic parasites circulating in synanthropic and pacific colonies of South American sea lions (Otaria flavescens): non-invasive techniques data and a review of the literature

Since late 1970s, the southern Chilean city Valdivia constitutes home for a unique bachelor group of South American sea lions (Otaria flavescens), initially descendant from colonies at the Pacific coast, but now directly living in a freshwater habitat in close proximity to human population and a vast amount of wild and domestic animal species. In the framework of a parasitological monitoring program, 115 individual fecal samples were collected from synanthropic South American sea lions between March and May 2018. For comparative reasons, 79 individual fecal samples from two free-living O. flavescens colonies at the Pacific coast were also sampled. Coproscopical analyses revealed the presence of nine different parasite taxa in individual fecal samples, including two protozoan (Cryptosporidium spp. and Giardia spp.) and seven metazoan parasites (Anisakidae gen. spp., Diphyllobothriidae gen. spp., Ogmogaster heptalineatus, Trematoda indet. type 1, Trematoda indet. type 2, Otostrongylus circumlitus, and Parafilaroides spp.), and morphological and molecular characterizations of adult helminths confirmed identification of following species: Anisakis simplex/A. pegreffi, Pseudoterranova cattani, Contracaecum ogmorhini, and Adenocephalus pacificus. For the first time, the results of the current study show the presence of zoonotic relevant Giardia- and Cryptosporidium-infections in two free-ranging colonies of South American sea lions apart from human settlement. Furthermore, a detailed literature search of previous publications on the endoparasite fauna of South American sea lions was conducted, revealing reports of at least 50 protozoan and metazoan parasite taxa including findings of the current study. Thereby, at least 25 of reported taxa (50%) have been recorded to bear zoonotic potential. The present study illustrates a successful application of non-invasive screening methods and their applicability in the field of marine mammal parasitology, bringing new insights into the endogenous parasite fauna of South American sea lions in Southern Chile, including anthropozoonotic protozoan and metazoan taxa

Benchmarking microwave-induced CO2_2 plasma splitting against electrochemical CO2_2 reduction for a comparison of promising technologies

Plasma conversion technology is an emerging technique under development to activate, convert or valorize gas molecules such as CO$_2$, N$_2$, CH$_4$, NH$_3$ and others. A large-scale application beyond the lab-scale demonstrator unit requires assessment of the efficiency of this new technology. The straightforward approach for assessment of the efficiency is benchmarking with the other well-established technologies of similar technology readiness level (TRL). In this paper we present a benchmarking of the atmospheric pressure microwave-induced CO$_2$ plasma splitting with electrochemical CO$_2$ conversion, via both low-temperature and high-temperature electrolysis. An additional step of oxygen removal in case of the plasma reactor is implemented due to the difference in the output stream of the plasma (gas mixture containing CO$_2$, CO, and O$_2$) and the electrochemical reactor (typical gas mixture on cathode containing CO$_2$ and CO). For the benchmarking, a comprehensive set of comparison parameters that are applicable for both the plasma and the electrochemical route is identified and grouped in three comparison categories: performance, interfaces, and economics. The comparison of these parameters demonstrates that in terms of the electric power consumption (EPC; power required for production of one Nm$^3_{CO}$) plasma conversion technology (∼20 kWh/Nm$^3_{CO}$) is in the ballpark with the other two electrochemical technologies (∼4–20 kWh/Nm$^3_{CO}$). The key features of the plasma conversion technology are relatively large conversion (up to 56%) and moderate energy efficiencies (up to 27%). Also, CO$_2$ gas of reduced purity of only 98% can be used without decrease of the performance, and CO output values are currently at 3.5 slm (standard litre per minute). Fast on/off response time of order of minutes, and no need for the hot standby indicate that the plasma conversion is particularly suitable for use of intermittent renewable energy sources. The aspects that require further development include optimization of the process towards lower EPC$_{total}$ values, improved oxygen gas separation, and reliable ignition of the plasma

Regulation of proteasome assembly and activity in health and disease

The proteasome degrades most cellular proteins in a controlled and tightly regulated manner and thereby controls many processes, including cell cycle, transcription, signalling, trafficking and protein quality control. Proteasomal degradation is vital in all cells and organisms, and dysfunction or failure of proteasomal degradation is associated with diverse human diseases, including cancer and neurodegeneration. Target selection is an important and well-established way to control protein degradation. In addition, mounting evidence indicates that cells adjust proteasome-mediated degradation to their needs by regulating proteasome abundance through the coordinated expression of proteasome subunits and assembly chaperones. Central to the regulation of proteasome assembly is TOR complex 1 (TORC1), which is the master regulator of cell growth and stress. This Review discusses how proteasome assembly and the regulation of proteasomal degradation are integrated with cellular physiology, including the interplay between the proteasome and autophagy pathways. Understanding these mechanisms has potential implications for disease therapy, as the misregulation of proteasome function contributes to human diseases such as cancer and neurodegeneration.</p

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants

BACKGROUND: One of the global targets for non-communicable diseases is to halt, by 2025, the rise in the age-standardised adult prevalence of diabetes at its 2010 levels. We aimed to estimate worldwide trends in diabetes, how likely it is for countries to achieve the global target, and how changes in prevalence, together with population growth and ageing, are affecting the number of adults with diabetes. METHODS: We pooled data from population-based studies that had collected data on diabetes through measurement of its biomarkers. We used a Bayesian hierarchical model to estimate trends in diabetes prevalence—defined as fasting plasma glucose of 7·0 mmol/L or higher, or history of diagnosis with diabetes, or use of insulin or oral hypoglycaemic drugs—in 200 countries and territories in 21 regions, by sex and from 1980 to 2014. We also calculated the posterior probability of meeting the global diabetes target if post-2000 trends continue. FINDINGS: We used data from 751 studies including 4 372 000 adults from 146 of the 200 countries we make estimates for. Global age-standardised diabetes prevalence increased from 4·3% (95% credible interval 2·4–7·0) in 1980 to 9·0% (7·2–11·1) in 2014 in men, and from 5·0% (2·9–7·9) to 7·9% (6·4–9·7) in women. The number of adults with diabetes in the world increased from 108 million in 1980 to 422 million in 2014 (28·5% due to the rise in prevalence, 39·7% due to population growth and ageing, and 31·8% due to interaction of these two factors). Age-standardised adult diabetes prevalence in 2014 was lowest in northwestern Europe, and highest in Polynesia and Micronesia, at nearly 25%, followed by Melanesia and the Middle East and north Africa. Between 1980 and 2014 there was little change in age-standardised diabetes prevalence in adult women in continental western Europe, although crude prevalence rose because of ageing of the population. By contrast, age-standardised adult prevalence rose by 15 percentage points in men and women in Polynesia and Micronesia. In 2014, American Samoa had the highest national prevalence of diabetes (>30% in both sexes), with age-standardised adult prevalence also higher than 25% in some other islands in Polynesia and Micronesia. If post-2000 trends continue, the probability of meeting the global target of halting the rise in the prevalence of diabetes by 2025 at the 2010 level worldwide is lower than 1% for men and is 1% for women. Only nine countries for men and 29 countries for women, mostly in western Europe, have a 50% or higher probability of meeting the global target. INTERPRETATION: Since 1980, age-standardised diabetes prevalence in adults has increased, or at best remained unchanged, in every country. Together with population growth and ageing, this rise has led to a near quadrupling of the number of adults with diabetes worldwide. The burden of diabetes, both in terms of prevalence and number of adults affected, has increased faster in low-income and middle-income countries than in high-income countries. FUNDING: Wellcome Trust